DAIC

MAY 6, 2024

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Frontiers in Cardiovascular Medicine

MARCH 3, 2024

Introduction Heart failure with preserved ejection fraction (HFpEF) is a complex disease process influenced by metabolic disorders, systemic inflammation, myocardial fibrosis, and microvascular dysfunction. Only 1 biomarker significantly correlated with both ECV and MPR.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Biomarkers Heart Failure 64

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Heart failure with preserved ejection fraction (HFpEF) is the largest unmet clinical need in cardiovascular medicine. Finally, we discuss the potential of ncRNAs as biomarkers and potential novel therapeutic targets for future HFpEF treatment.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Biomarkers Cardiovascular Disease 59

Frontiers in Cardiovascular Medicine

JANUARY 28, 2024

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Atrial Fibrillation Electrophysiology 59

Circulation: Heart Failure

OCTOBER 23, 2023

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Biomarkers Exercise 40

Heart BMJ

FEBRUARY 23, 2024

Objective The heterogeneous pathophysiology of the diverse heart failure with preserved ejection fraction (HFpEF) phenotypes needs to be examined. We aim to assess differences in the biomarkers among the phenotypes of HFpEF and investigate its multifactorial pathophysiology.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Biomarkers Hypertension 40

Journal of the American Heart Association

FEBRUARY 14, 2024

Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We In addition, renal injury, oxidative stress, inflammation, and profibrotic biomarkers were evaluated to determine pathways associated with RDN.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Blood Pressure Biomarkers 40